Shenzhen Magicrna Biotechnology Co., Ltd
Clinical trials sponsored by Shenzhen Magicrna Biotechnology Co., Ltd, explained in plain language.
-
New CAR-T therapy aims to calm overactive immune system in muscle weakness disease
Disease control Not yet recruitingThis early study tests a new treatment called HN2301 in 6 adults with generalized myasthenia gravis, a disease that causes muscle weakness. The treatment uses the body's own immune cells to target and reduce harmful immune activity. The main goal is to check safety and see how we…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a single injection reprogram immune cells to tame lupus and scleroderma?
Disease control Not yet recruitingThis early study tests a new drug called HN2302, which aims to create CAR-T cells inside the body to target and control autoimmune diseases like lupus and scleroderma. The trial will enroll 12 adults to check safety and see if the treatment works. It is a first step, so results w…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC